Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| HUM00098103 | Other Identifier | University of Michigan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Patient Reported Adherence | No Intervention | Adherence assessment via phone call or in person | |
| Smart Phone Application | Active Comparator | Adherence assessment via phone app |
|
| POD and Smart Phone Application | Experimental | Adherence assessment via phone app partnered with an automated dispensing machine, a "Pod." |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smart Phone Application | Other | Oral medication adherence phone application. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The change in the number of patients that report high adherence over time via smart phone application alone | Adherence will be assessed via smart phone application at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). | 0, 4, 8 and 12 weeks |
| The change in the number of patients that report high adherence over time via smart phone application and POD | Adherence will be assessed via smart phone application + POD at baseline, 4, 8 and 12 weeks. Adherence reported via the phone application will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). For the Pod there will be continuous adherence assessed via the pod each time the patient administers or does not administer a scheduled dose. This will be figured into the overall adherence rating. | 0, 4, 8 and 12 weeks |
| The change in the number of patients that report high adherence over time via telephone/face-to-face visit (self-reported) | Adherence will be assessed via telephone/face-to-face visit (self-reported) at baseline, 4, 8 and 12 weeks. Self-reported adherence will be done using an adherence question assessment.This assessment is ordinal in nature and asks the patient to rate their adherence on a scale (poor, fair, good, very good, excellent). | 0, 4, 8 and 12 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shawna Kraft, Pharm.D., BCOP | University of Michigan Rogel Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| POD | Other | Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center. |
|